# Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)

> **NCT01635777** · PHASE2 · COMPLETED · sponsor: **AB Foundation** · enrollment: 37 (actual)

## Conditions studied

- PKDL

## Interventions

- **DRUG:** Miltefosine
- **DRUG:** Miltefosine

## Key facts

- **NCT ID:** NCT01635777
- **Lead sponsor:** AB Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-10
- **Final completion:** 2010-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2012-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01635777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01635777, "Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01635777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*